Aztreonam

435.43

435.43

278-839-9

DTXSID0022640

J01DF01|J - Antiinfectives for systemic use

29419000

238

0.81830

solid

1.83

227°C

1.74

soluble in DMF/water (1:1) at 50 mg/ml

Store at 0-5°C

Abdominal-rat LD50: 2549 mg/kg; Abdominal-mouse LD50: 2897 mg/kg

Flammable; burning produces toxic nitrogen oxides and sulfur oxide fumes

Ⅲ

2811

2

20/21/22-36/37/38

22-24/25-36-26

UA2451400

Xn

Ventilated, low temperature and dry

|Danger|H317 (50%): May cause an allergic skin reaction [Warning Sensitization, Skin]|P261, P272, P273, P280, P285, P302+P352, P304+P341, P321, P333+P313, P342+P311, P363, P391, and P501|Aggregated GHS information provided by 4 companies from 3 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

moderately toxic

Aztreonam has systemic toxicities that are similar to those of other beta lactam antibiotics, but it is unclear whether it can cause hepatic injury similar to that of the penicillins or cephalosporins. Asymptomatic serum aminotransferase elevations are common during high dose, intravenous aztreonam therapy (10% to 38%). The enzyme abnormalities are usually mild-to-moderate, asymptomatic, self-limited and not requiring drug discontinuation. Enzyme elevations occur slightly more commonly during aztreonam therapy than with other comparative antibiotics. Cases of frank liver injury and jaundice attributable to aztreonam must be extremely rare as no individual cases have been reported. For this reason, there is no data regarding the latency or pattern of the injury. Instances of marked aminotransferase elevations within 3 to 5 days of starting aztreonam have been reported, but these cases were without jaundice and resolved rapidly once the drug was stopped.

Cayston is indicated for the suppressive therapy of chronic pulmonary infections due to Pseudomonas aeruginosa in patients with cystic fibrosis (CF) aged 6 years and older.Consideration should be given to official guidance on the appropriate use of antibacterial agents.|Treatment of Gram-negative endobronchial infection in bronchiectasis patients|Treatment of infections caused by aerobic gram-negative bacteria|Treatment of Pseudomonas aeruginosa pulmonary infection / colonisation in patients with cystic fibrosis

Aztreonam is a parenterally administered, synthetic monobactam antibiotic that is specifically active against aerobic gram-negative bacilli is resistant to many beta-lactamases. Aztreonam therapy is often accompanied by mild, asymptomatic elevations in serum aminotransferase levels, but it has not been reported to cause clinically apparent liver injury.

Antiinfective Agents

Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)

Az threonam

Human drugs -> Cayston -> EMA Drug Category|Antibacterials for systemic use -> Human pharmacotherapeutic group|Human Drugs -> EU pediatric investigation plans|Human Drugs -> FDA Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) -> Active Ingredients